TITLE

Relocating abroad

AUTHOR(S)
Lee, Jaimy
PUB. DATE
October 2011
SOURCE
Modern Healthcare;10/24/2011, Vol. 41 Issue 43, p32
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
the article discusses the role played by the U.S. Food and Drug Administration (FDA) in monitoring clinical trials for FDA-regulated products conducted outside the U.S. A 2010 Health and Human Services (HHS) inspector general's report revealed that up to 65 per cent of these clinical trials are done in other countries. The agency is exerting efforts to address the proliferation of counterfeit or adulterated drugs, including their global supply chains.
ACCESSION #
66967531

 

Related Articles

  • FDA Recommendations to Industry Regarding Outsourcing. Swider, Marlen Garcia // BioPharm International;Apr2009 Supplement, p6 

    The article discusses guidance from the U.S. Food and Drug Administration on how to ensure compliance in outsourcing. The economic conditions that affect the capability of drug manufacturers to perform manufacturing operations at their establishments are tackled. The complexity that outsourcing...

  • News Update.  // Applied Clinical Trials;Sep2000, Vol. 9 Issue 9, p14 

    Reports developments related to clinical trials in the United States as of September 2000. Approval of several health-related drugs by the Food and Drug Administration; Results of clinical trials on cancer and hypertension treatment; Details on the approval of the orphan drug status to Cell...

  • Pediatric Safety Rule Momentum in Congress.  // Chemical Market Reporter;1/6/2003, Vol. 263 Issue 1, p7 

    Reports on a legislation giving the U.S. Food and Drug Administration authority to require pharmaceutical companies to conduct clinical trials to determine whether drugs and biologics are safe and effective in children. Incentives given by the Best Pharmaceutical for Children Act for drug makers.

  • In Vitro to the Rescue. Bode, Chris // Applied Clinical Trials;Jun2008, Vol. 17 Issue 6, p180 

    The article focuses on the importance of the Critical Path Initiative developed by the U.S. Food and Drug Administration (FDA) for the vitro Absorption, Distribution, Metabolism and Excretion (ADME) models. The scheme will modernize and speed up the development process which will focus on...

  • Pediatric Mandate. Keeney, Ronald // Pharmaceutical Executive;Apr2001, Vol. 21 Issue 4, p98 

    Explores how the pharmaceutical industry of the United States (U.S.) can change its approach to pediatric clinical trials in line with the U.S. Food and Drug Administration's (FDA) regulations mandating pediatric studies for drugs and biologicals. FDA initiatives in line with the issue of...

  • FDA Revises Field Inspections to Reflect Global Market and Quality Initiatives. Wechsler, Jill // BioPharm International;May2015, Vol. 28 Issue 5, p8 

    The article reports that the U.S. Food and Drug Administration (FDA) is enhancing its inspection authorities due to the globalization of drug production. Topics discussed include choosing India to adopt strict enforcement in plant inspections, restructuring the Office of Regulatory Affairs (ORA)...

  • By the Numbers.  // Contract Pharma;May2013, Vol. 15 Issue 4, p51 

    Statistics related to the results of a 2013 outsourcing survey in the pharmaceutical industry are presented, including one on the percentage of respondents who employ secondary suppliers for their commercial supply, one on the percentage of respondents whose active pharmaceutical ingredients...

  • Are drugs made abroad safe to take?  // Consumer Reports on Health;Sep2014, Vol. 26 Issue 9, p9 

    The article discusses safety issues that have been found to be associated with medications that are sold in the U.S. and are manufactured in foreign countries, including India and China. Warning letters related to drug manufacturing which the U.S. Food and Drug Administration sent to drug...

  • Bad medicine. Grens, Kerry // Modern Healthcare;5/20/2013, Vol. 43 Issue 20, p30 

    The article discusses the global efforts to stop the use of poor-quality drugs. The World Health Organization (WHO) revealed that 30% of United Nations (UN) members do not have adequate regulatory oversight of drugs. Non-profit organization U.S. Pharmacopoeia (USP) has launched a program to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics